Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov;12(6):383-94.
doi: 10.1007/s11912-010-0132-1.

Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy

Andrew M Evens  1 , Rupali Roy, Danielle Sterrenberg, Michelle Z Moll, Amy Chadburn, Leo I Gordon
Affiliations
Review

Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy

Andrew M Evens et al. Curr Oncol Rep. 2010 Nov.

Abstract

Post-transplantation lymphoproliferative disorders (PTLD) are a heterogenous group of abnormal lymphoid proliferations that occur after solid organ transplant (SOT) or hematopoietic transplantation. PTLDs consist of a disease spectrum ranging from hyperplasia to aggressive lymphomas with 60-70% being Epstein-Barr virus positive. The majority of cases are B-cell, although 10-15% are of T-cell origin or rarely Hodgkin lymphoma. Recent SOT series suggest PTLD occurs at a median of 36-40 months after transplant. Clinically, extra-nodal disease is common (up to 75-85%) including CNS involvement, which is seen in 10-15% of all cases. Since the first report over 40 years ago, PTLD has remained one of the most morbid complications associated with SOT. However, recent data suggests improved survival in the modern era, especially with the integration of early rituximab-based therapy. These studies utilized first line rituximab (+/- chemotherapy) together with reduced immune suppression (RI) for monomorphic and polymorphic PTLD. It will be critical in future studies to determine which PTLDs are most amenable to initial therapy with RI alone, versus RI/rituximab, versus RI/rituximab/chemotherapy. Additionally, novel therapeutics, such as adoptive immunotherapy, should continue to be explored.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Blood. 2010 Apr 8;115(14):2960-70 - PubMed
    1. Leuk Lymphoma. 2005 Feb;46(2):191-6 - PubMed
    1. Br J Haematol. 2008 Jan;140(2):191-6 - PubMed
    1. Bone Marrow Transplant. 2008 Jan;41(2):193-8 - PubMed
    1. Blood. 2001 Mar 15;97(6):1590-7 - PubMed

MeSH terms

Substances

LinkOut - more resources

-